f approx. $300 m in the us . 70% of Val sales were for transplant patients l$200 m) 24 24 EFTA00506093 EBV-Transplant Phase 2 Trial (EPB-348) Design & Milestones Study Design • Double-blinded, placebo controlled • 40 transplant recipients with EBV wernia • Primary Endpoint: Virologk response to therapy